Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[68Ga]DOTA-IR-780-C-4 PET Imaging in Prostate Cancer
NCT07162779Enrolling by invitation
- Sponsor
- Affiliated Hospital of Jiangnan University
- Start
- Oct 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of [68Ga]DOTA-IR-780-C-4 in prostate cancer (PCa), sponsored by Affiliated Hospital of Jiangnan University. Primary endpoint: The dection performance of radiotracer [68Ga]DOTA-IR-780-C-4 at 3 hours. Started Oct 2024; status: enrolling by invitation.
02
Drugs
[68Ga]DOTA-IR-780-C-4
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07162779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07162779.